Sugi Predict

Sugi Predict / Compounds / SCHEMBL13446629

SCHEMBL13446629

SCHEMBL13446629

[N-]=[N+]=NCCCCCCCCCCCCCCCC(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 5/20 0.55
▸ LMNA P02545 3/20 0.55
▸ NFKB1 P19838 1/20 0.55
▸ PMP22 Q01453 1/20 0.55
▸ GPR84 Q9NQS5 8/20 0.46
▸ FFAR1 O14842 2/20 0.46
▸ FFAR4 Q5NUL3 2/20 0.46
▸ PPARG P37231 7/20 0.44
▸ PPARD Q03181 7/20 0.44
▸ PPARA Q07869 7/20 0.44
▸ HDAC11 Q96DB2 5/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ PTPN1 P18031 3/20 0.44
▸ TLR2 O60603 2/20 0.44
▸ TDP1 Q9NUW8 2/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ FABP4 P15090 2/20 0.44
▸ ALOX15 P16050 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ SLC22A6 Q4U2R8 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15288850 1.00 TSHR (0.55) TSHRLMNANFKB1PMP22GPR84
SCHEMBL16506913 1.00 TSHR (0.55) TSHRLMNANFKB1PMP22GPR84
SCHEMBL13895485 1.00 TSHR (0.55) TSHRLMNANFKB1PMP22GPR84
SCHEMBL25263751 1.00 TSHR (0.55) TSHRLMNANFKB1PMP22GPR84
SCHEMBL13651619 1.00 TSHR (0.55) TSHRLMNANFKB1PMP22GPR84
SCHEMBL25408049 1.00 TSHR (0.55) TSHRLMNANFKB1PMP22GPR84
SCHEMBL13736453 1.00 TSHR (0.55) TSHRLMNANFKB1PMP22GPR84
SCHEMBL14129678 1.00 TSHR (0.55) TSHRLMNANFKB1PMP22GPR84
SCHEMBL20626797 1.00 TSHR (0.55) TSHRLMNANFKB1PMP22GPR84
SCHEMBL13866617 1.00 TSHR (0.55) TSHRLMNANFKB1PMP22GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3448417-B1 INSULIN DIMER-INCRETIN CONJUGATES MERCK SHARP & DOHME LLC (US) 2025-11-12 — — EP disclosed
US-20230105982-A1 INSULIN-INCRETIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2023-04-06 — — US disclosed
US-20220339259-A1 ORALLY DELIVERED THERAPEUTICAL COMPOSITION AND USE THEREOF SHEN HAIFA (US) 2022-10-27 — — US disclosed
CN-114466658-A Orally delivered therapeutic compositions and uses thereof 沈海发 2022-05-10 — — CN disclosed
US-11058775-B2 Insulin dimer-incretin conjugates MERCK SHARP & DOHME CORP. (US) 2021-07-13 — — US disclosed
WO-2021046497-A2 ORALLY DELIVERED THERAPEUTICAL COMPOSITION AND USE THEREOF SHEN HAIFA (US) 2021-03-11 — — WO disclosed
US-20190192675-A1 INSULIN DIMER-INCRETIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2019-06-27 — — US disclosed
US-20190175744-A1 INSULIN-INCRETIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2019-06-13 — — US disclosed
EP-3430033-A1 INSULIN-INCRETIN CONJUGATES Merck Sharp & Dohme Corp. (US) 2019-01-23 — — EP disclosed
US-20170362624-A1 LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS Life Technologies Corporation 2017-12-21 — — US disclosed
EP-1613641-B1 CHOLESTEROL-CONTAINING COMPOUNDS AND THEIR USE AS IMMUNOGENS AGAINST BORRELIA BURGDORFERI US GOV HEALTH & HUMAN SERV (US) 2009-01-14 — — EP disclosed
WO-2008029281-A2 LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS INVITROGEN CORPORATION (US) 2008-03-13 — — WO disclosed
US-20070249014-A1 LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS INVITROGEN CORPORATION (US) 2007-10-25 — — US disclosed
US-20070249014-A1 LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS INVITROGEN CORPORATION (US) 2007-10-25 — — US disclosed
EP-0525479-B1 Spicamycin derivatives and the use thereof KIRIN BREWERY (JP) 1997-11-05 — — EP disclosed
US-5631238-A ANTICARCINOGENIC AGENTS KIRIN BEER KABUSHIKI KAISHA (JP) 1997-05-20 — — US disclosed
CN-1033227-C Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and their use. SANKYO CO (JP) 1996-11-06 — — CN disclosed
US-5461036-A Treating colon, gastric, esophageal cancer KIRIN BEER KABUSHIKI KAISHA (JP) 1995-10-24 — — US disclosed
CN-1072686-A Has Pyrmidine nucleoside derivatives of anti-tumor activity and its production and use SANKYO CO (JP) 1993-06-02 — — CN disclosed
EP-0525479-A1 Spicamycin derivatives and the use thereof KIRIN BEER KABUSHIKI KAISHA (JP) 1993-02-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190175744-A1 INSULIN-INCRETIN CONJUGATES GIPR, GLP1R, GCGR TSHR 116/4885LMNA 4509/4885NFKB1 4439/4885
US-20230105982-A1 INSULIN-INCRETIN CONJUGATES GIPR, GLP1R, GCGR TSHR 116/4885LMNA 4509/4885NFKB1 4439/4885
US-20190192675-A1 INSULIN DIMER-INCRETIN CONJUGATES IAPP, GLP1R, GIPR TSHR 455/4885LMNA 3687/4885NFKB1 3046/4885
US-11058775-B2 Insulin dimer-incretin conjugates IAPP, GLP1R, GIPR TSHR 455/4885LMNA 3687/4885NFKB1 3046/4885
US-20220339259-A1 ORALLY DELIVERED THERAPEUTICAL COMPOSITION AND USE THEREOF FABP2, SLC27A1, SLC27A2 TSHR 4550/4885LMNA 2441/4885NFKB1 2951/4885
US-20070249014-A1 LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS PTMS, DNPEP, BTD TSHR 3349/4885LMNA 2858/4885NFKB1 3181/4885
US-20170362624-A1 LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS PTMS, DNPEP, BTD TSHR 3349/4885LMNA 2858/4885NFKB1 3181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.